Cargando…

The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment

BACKGROUND: Hepatitis B virus (HBV) can encode microRNA-HBV-miR-3, which can be detected in both HBV-infected cell lines and peripheral blood exosomes of chronic hepatitis B (CHB) patients. This study was conducted to further evaluate its relationship with the current viral markers and their dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Weiqiang, Chen, Xi, Wu, Zeqian, Zhu, Xiang, Liu, Jing, Wang, Tong, Gao, Zhiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201139/
https://www.ncbi.nlm.nih.gov/pubmed/35722385
http://dx.doi.org/10.21037/atm-22-2119
_version_ 1784728234855759872
author Gan, Weiqiang
Chen, Xi
Wu, Zeqian
Zhu, Xiang
Liu, Jing
Wang, Tong
Gao, Zhiliang
author_facet Gan, Weiqiang
Chen, Xi
Wu, Zeqian
Zhu, Xiang
Liu, Jing
Wang, Tong
Gao, Zhiliang
author_sort Gan, Weiqiang
collection PubMed
description BACKGROUND: Hepatitis B virus (HBV) can encode microRNA-HBV-miR-3, which can be detected in both HBV-infected cell lines and peripheral blood exosomes of chronic hepatitis B (CHB) patients. This study was conducted to further evaluate its relationship with the current viral markers and their dynamics during antiviral therapy. METHODS: We used Stem-loop real time quantitative PCR (RT-qPCR) to quantify HBV-miR-3 in the serum exosomes of CHB patients by extracting exosomes using the Supbio exosome separation kit and designing primers and Taqman probes specific for HBV-miR-3. We conducted a cross-sectional study and two cohort studies. In the cross-sectional study, 48 treatment-naive (TN) CHB patients were enrolled. In the nucleoside analogues (NAs) cohort study, 20 hepatitis B e antigen (HBeAg) negative CHB patients with negative HBV DNA on NA therapy were followed up for 96 weeks. In the NAs + pegylated interferon (Peg-IFN) cohort study, 40 patients with hepatitis B surface antigen (HBsAg) <1,500 IU/mL, negative HBV DNA, and HBeAg after NAs treatment were enrolled and were switched to Peg-IFN therapy for 48 weeks. HBV-miR-3 titers and other viral markers were detected at different time points. RESULTS: HBV-miR-3 only existed in CHB patients with a concentration of 6.41±3.55 log10 copies/mL. HBV-miR-3 was positively correlated with HBV DNA, pregenomic RNA (pgRNA), and HBsAg. In the NAs cohort, HBsAg, pgRNA, and HBV-miR-3 levels showed little fluctuation during the 96 weeks of NA treatment (P>0.05). In the NAs + PEG-IFN cohort, HBsAg, pgRNA, and HBV-miR-3 levels declined significantly during the 48 weeks of sequential therapy (P<0.05). CONCLUSIONS: HBV-miR-3 was positively correlated with HBV DNA, pgRNA, and particularly HBsAg in TN CHB patients. Peg-IFN following NA therapy had a positive impact on HBsAg, pgRNA, and HBV-miR-3 decrease.
format Online
Article
Text
id pubmed-9201139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-92011392022-06-17 The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment Gan, Weiqiang Chen, Xi Wu, Zeqian Zhu, Xiang Liu, Jing Wang, Tong Gao, Zhiliang Ann Transl Med Original Article BACKGROUND: Hepatitis B virus (HBV) can encode microRNA-HBV-miR-3, which can be detected in both HBV-infected cell lines and peripheral blood exosomes of chronic hepatitis B (CHB) patients. This study was conducted to further evaluate its relationship with the current viral markers and their dynamics during antiviral therapy. METHODS: We used Stem-loop real time quantitative PCR (RT-qPCR) to quantify HBV-miR-3 in the serum exosomes of CHB patients by extracting exosomes using the Supbio exosome separation kit and designing primers and Taqman probes specific for HBV-miR-3. We conducted a cross-sectional study and two cohort studies. In the cross-sectional study, 48 treatment-naive (TN) CHB patients were enrolled. In the nucleoside analogues (NAs) cohort study, 20 hepatitis B e antigen (HBeAg) negative CHB patients with negative HBV DNA on NA therapy were followed up for 96 weeks. In the NAs + pegylated interferon (Peg-IFN) cohort study, 40 patients with hepatitis B surface antigen (HBsAg) <1,500 IU/mL, negative HBV DNA, and HBeAg after NAs treatment were enrolled and were switched to Peg-IFN therapy for 48 weeks. HBV-miR-3 titers and other viral markers were detected at different time points. RESULTS: HBV-miR-3 only existed in CHB patients with a concentration of 6.41±3.55 log10 copies/mL. HBV-miR-3 was positively correlated with HBV DNA, pregenomic RNA (pgRNA), and HBsAg. In the NAs cohort, HBsAg, pgRNA, and HBV-miR-3 levels showed little fluctuation during the 96 weeks of NA treatment (P>0.05). In the NAs + PEG-IFN cohort, HBsAg, pgRNA, and HBV-miR-3 levels declined significantly during the 48 weeks of sequential therapy (P<0.05). CONCLUSIONS: HBV-miR-3 was positively correlated with HBV DNA, pgRNA, and particularly HBsAg in TN CHB patients. Peg-IFN following NA therapy had a positive impact on HBsAg, pgRNA, and HBV-miR-3 decrease. AME Publishing Company 2022-05 /pmc/articles/PMC9201139/ /pubmed/35722385 http://dx.doi.org/10.21037/atm-22-2119 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Gan, Weiqiang
Chen, Xi
Wu, Zeqian
Zhu, Xiang
Liu, Jing
Wang, Tong
Gao, Zhiliang
The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title_full The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title_fullStr The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title_full_unstemmed The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title_short The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment
title_sort relationship between serum exosome hbv-mir-3 and current virological markers and its dynamics in chronic hepatitis b patients on antiviral treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201139/
https://www.ncbi.nlm.nih.gov/pubmed/35722385
http://dx.doi.org/10.21037/atm-22-2119
work_keys_str_mv AT ganweiqiang therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT chenxi therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT wuzeqian therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT zhuxiang therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT liujing therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT wangtong therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT gaozhiliang therelationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT ganweiqiang relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT chenxi relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT wuzeqian relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT zhuxiang relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT liujing relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT wangtong relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment
AT gaozhiliang relationshipbetweenserumexosomehbvmir3andcurrentvirologicalmarkersanditsdynamicsinchronichepatitisbpatientsonantiviraltreatment